Published in Blood on December 13, 2005
Oral Nifedipine to Treat Iron Overload | NCT00712738
Clinical Importance of Treating Iron Overload in Sickle Cell Disease | NCT00981370
Iron-chelating therapy for transfusional iron overload. N Engl J Med (2011) 3.92
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Beta-thalassemia. Orphanet J Rare Dis (2010) 3.06
The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest (2007) 2.48
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood (2006) 1.81
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol (2007) 1.77
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica (2009) 1.73
Body iron metabolism and pathophysiology of iron overload. Int J Hematol (2008) 1.59
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood (2014) 1.54
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Deferasirox-induced renal impairment in children: an increasing concern for pediatricians. Pediatr Nephrol (2012) 1.45
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol (2011) 1.45
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol (2009) 1.40
Cardiac iron across different transfusion-dependent diseases. Blood Rev (2008) 1.37
Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep (2010) 1.31
The treatment of secondary hemochromatosis. Dtsch Arztebl Int (2009) 1.24
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
Liver iron content determination by magnetic resonance imaging. World J Gastroenterol (2010) 1.21
HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood (2010) 1.20
An update on iron chelation therapy. Blood Transfus (2012) 1.19
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica (2010) 1.19
Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag (2007) 1.14
Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson (2014) 1.13
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Expert Opin Drug Saf (2013) 1.11
The heart in transfusion dependent homozygous thalassaemia today--prediction, prevention and management. Eur J Haematol (2007) 1.10
The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes (2006) 1.07
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica (2012) 1.07
Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood (2009) 1.04
The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson (2009) 1.00
Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol (2009) 0.99
Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. Eur J Haematol (2011) 0.99
What is new in iron overload? Eur J Pediatr (2007) 0.99
Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood (2012) 0.98
Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest (2008) 0.98
Molecular and clinical aspects of iron homeostasis: From anemia to hemochromatosis. Wien Klin Wochenschr (2006) 0.97
Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol (2008) 0.96
Does liver biopsy overestimate liver iron concentration? Blood (2006) 0.95
Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem (2009) 0.94
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion (2008) 0.94
Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire. J Pediatr Hematol Oncol (2010) 0.94
Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med (2012) 0.92
Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia. Oman Med J (2013) 0.92
Curcumin Attenuates Iron Accumulation and Oxidative Stress in the Liver and Spleen of Chronic Iron-Overloaded Rats. PLoS One (2015) 0.92
Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget (2015) 0.91
Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag (2007) 0.91
Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med (2011) 0.90
Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis (2012) 0.90
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson (2013) 0.89
A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology (2010) 0.88
Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J (2014) 0.88
Iron chelation therapy in myelodysplastic syndromes. Adv Hematol (2010) 0.87
Italian Society of Hematology guidelines for thalassemia and non-invasive iron measurements. Haematologica (2008) 0.86
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion. Rev Bras Hematol Hemoter (2013) 0.86
Terephthalamide-containing ligands: fast removal of iron from transferrin. J Biol Inorg Chem (2007) 0.86
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PLoS One (2013) 0.85
Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. Clin Exp Metastasis (2007) 0.85
Quality of life in patients with thalassemia major. Iran J Ped Hematol Oncol (2014) 0.85
Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review. Ther Adv Hematol (2013) 0.83
Determination of ferritin and hemosiderin iron in patients with normal iron stores and iron overload by serum ferritin kinetics. Nagoya J Med Sci (2012) 0.83
Recent advances in β-thalassemias. Pediatr Rep (2011) 0.82
Hematopietic stem cell transplantation in thalassemia and related disorders. Mediterr J Hematol Infect Dis (2009) 0.82
Pharmacogenetic study of deferasirox, an iron chelating agent. PLoS One (2013) 0.82
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica (2012) 0.81
Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections. Curr Opin Microbiol (2015) 0.81
Recent advances in treatment of aplastic anemia. Korean J Intern Med (2014) 0.81
Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol (2008) 0.81
Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int (2013) 0.80
Deferasirox: appraisal of safety and efficacy in long-term therapy. J Blood Med (2013) 0.80
Update on the use of deferasirox in the management of iron overload. Ther Clin Risk Manag (2009) 0.80
Pharmacology of iron transport. Annu Rev Pharmacol Toxicol (2012) 0.79
Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area. Orphanet J Rare Dis (2013) 0.79
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Ann Hematol (2012) 0.79
[Individualized management and therapy of myelodysplastic syndromes]. Wien Klin Wochenschr (2008) 0.78
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Eur J Haematol (2011) 0.78
Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med (2015) 0.78
Successful therapy of progressive rhino-orbital mucormycosis caused by Rhizopus arrhizus with combined and sequential antifungal therapy, surgery and hyperbaric therapy. Med Mycol Case Rep (2014) 0.78
Korean guideline for iron chelation therapy in transfusion-induced iron overload. J Korean Med Sci (2013) 0.78
Deferasirox in Indian children with thalassemia major: 3 years experience. Indian J Med Paediatr Oncol (2013) 0.78
Guidelines on haemovigilance of post-transfusional iron overload. Blood Transfus (2012) 0.78
Increasing and decreasing phases of ferritin and hemosiderin iron determined by serum ferritin kinetics. Nagoya J Med Sci (2013) 0.78
METABOLISM OF IRON STORES. Nagoya J Med Sci (2014) 0.78
Transferrin iron starvation therapy for lethal bacterial and fungal infections. J Infect Dis (2014) 0.78
Iron overload during follow-up after tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma. J Korean Med Sci (2012) 0.78
Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. Ther Clin Risk Manag (2016) 0.78
The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan. Ann Hematol (2015) 0.78
Prevention of cardiomyopathy in transfusion-dependent homozygous thalassaemia today and the role of cardiac magnetic resonance imaging. Adv Hematol (2009) 0.77
Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electron Physician (2016) 0.76
Does liver biopsy overestimate liver iron concentration? Blood (2006) 0.76
Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective. Pharmacoeconomics (2013) 0.76
β-Thalassemia Intermedia: A Bird's-Eye View. Turk J Haematol (2014) 0.76
Iron chelation therapy in thalassemia syndromes. Mediterr J Hematol Infect Dis (2009) 0.76
Management of the thalassemias. Cold Spring Harb Perspect Med (2013) 0.76
Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives. J Blood Med (2016) 0.76
The potential of deferasirox as a novel therapeutic modality in gastric cancer. World J Surg Oncol (2016) 0.75
Cardiac function and iron chelation in thalassemia major and intermedia: a review of the underlying pathophysiology and approach to chelation management. Mediterr J Hematol Infect Dis (2009) 0.75
Cost analysis of iron-related complications in a single institute. Korean J Intern Med (2009) 0.75
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA (2003) 8.18
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med (2007) 6.76
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood (2011) 6.50
Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A (2008) 5.27
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21
Successes and challenges of HIV prevention in men who have sex with men. Lancet (2012) 4.94
Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis (2011) 4.72
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
The use of deception in public health behavioral intervention trials: a case study of three online alcohol trials. Am J Bioeth (2013) 4.37
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet (2003) 3.07
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica (2008) 2.92
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood (2005) 2.75
Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica (2005) 2.66
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 2.64
Rac1 deletion in mouse neutrophils has selective effects on neutrophil functions. J Immunol (2003) 2.59
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54
Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica (2005) 2.53
Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica (2007) 2.52
Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet (2011) 2.51
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol (2009) 2.48
Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis (2004) 2.46
Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood (2013) 2.46
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45
Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol (2010) 2.43
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 2.41
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood (2007) 2.36
Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol (2005) 2.36
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) (2010) 2.33
Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood (2011) 2.29
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost (2006) 2.27
Beta-thalassemia. Genet Med (2010) 2.24
A severe alpha thalassemia case compound heterozygous for Hb Adana in alpha1 gene and 20.5 kb double gene deletion. J Pediatr Hematol Oncol (2009) 2.21
Factors associated with self-efficacy for condom use and sexual negotiation among South african youth. J Acquir Immune Defic Syndr (2006) 2.21
Indigenous peoples' health--why are they behind everyone, everywhere? Lancet (2005) 2.20
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood (2009) 2.20
Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med (2003) 2.19
X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J Exp Med (2006) 2.18
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica (2006) 2.14
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica (2008) 2.12
Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II. Nat Genet (2009) 2.12
Purging iron from the heart. Br J Haematol (2004) 2.07
Infantile hemangiomas, complications and follow-up. Indian Pediatr (2012) 2.04
Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol (2006) 1.99
Social networking technologies as an emerging tool for HIV prevention: a cluster randomized trial. Ann Intern Med (2013) 1.97
Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica (2003) 1.94
Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet (2009) 1.87
Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics (2005) 1.85
Disseminated cryptosporidium infection in an infant with hyper-IgM syndrome caused by CD40 deficiency. J Pediatr (2003) 1.84
Thalassemia. Hematology Am Soc Hematol Educ Program (2004) 1.83
Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood (2002) 1.83
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood (2009) 1.83
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol (2010) 1.79
HIV-related stigma, social norms, and HIV testing in Soweto and Vulindlela, South Africa: National Institutes of Mental Health Project Accept (HPTN 043). J Acquir Immune Defic Syndr (2010) 1.78
Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int (2004) 1.78
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood (2002) 1.77
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol (2007) 1.77
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson (2008) 1.76
Disappearing, displaced, and undervalued: a call to action for Indigenous health worldwide. Lancet (2006) 1.74
The relationship between online social networking and sexual risk behaviors among men who have sex with men (MSM). PLoS One (2013) 1.74
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica (2009) 1.73
Point: Sickle cell trait should be considered asymptomatic and as a benign condition during physical activity. J Appl Physiol (1985) (2007) 1.71
KLF1 gene mutations cause borderline HbA(2). Blood (2011) 1.71
Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood (2011) 1.71
In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. Blood Cells Mol Dis (2002) 1.70
Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood (2013) 1.68
Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav (2011) 1.66
Frameshift mutation in p53 regulator RPL26 is associated with multiple physical abnormalities and a specific pre-ribosomal RNA processing defect in diamond-blackfan anemia. Hum Mutat (2012) 1.64
Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis (2002) 1.63
Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood (2005) 1.61
Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res (2009) 1.61
Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS (2007) 1.60